A small molecule inhibitor of HER3: a proof-of-concept studyMore about Open Access at the Crick
Authors listAudrey Colomba Martina Fitzek Roger George Gregory Weitsman Selene Roberts Laura Zanetti-Domingues Michael Hirsch Daniel J Rolfe Shahid Mehmood Andrew Madin Jeroen Claus Svend Kjaer Bram Snijders Tony Ng Marisa Martin-Fernandez David M Smith Peter Parker
Despite being catalytically defective, pseudokinases are typically essential players of cellular signalling, acting as allosteric regulators of their active counterparts. Deregulation of a growing number of pseudokinases has been linked to human diseases, making pseudokinases therapeutic targets of interest. Pseudokinases can be dynamic, adopting specific conformations critical for their allosteric function. Interfering with their allosteric role, with small molecules that would lock pseudokinases in a conformation preventing their productive partner interactions, is an attractive therapeutic strategy to explore. As a well-known allosteric activator of EGFR family members, and playing a major part in cancer progression, the pseudokinase HER3 is a relevant context in which to address the potential of pseudokinases as drug targets for the development of allosteric inhibitors. In this proof-of-concept study, we developed a multiplex, medium throughput thermal-shift assay screening strategy to assess over 100,000 compounds and identify selective small molecule inhibitors that would trap HER3 in a conformation which is unfavourable for the formation of an active HER2-HER3 heterodimer. As a proof-of-concept compound, AC3573 bound with some specificity to HER3 and abrogated HER2-HER3 complex formation and downstream signalling in cells. Our study highlights the opportunity to identify new molecular mechanisms of action interfering with the biological function of pseudokinases.
Journal Biochemical Journal
Issue number 17
Discovery with a purpose - to improve people's health and wellbeing - is central to the Crick.
We conduct discovery science, aimed at solving human health challenges. Our translation and innovation strategy seeks to turn this science into improvements in the lives of people around the world, as well as generating economic opportunities.
We aim to improve lives by identifying possible therapies, diagnosis and disease prevention. This often offers opportunities to form new businesses and grow existing ones, creating highly skilled employment and the potential for other activities that reinforce the UK's position at the forefront of innovation in life sciences.
To realise these health benefits, we have created an environment where basic and clinical scientists can work together closely and effectively.
We don’t carry out patient-based research at The Crick, but we use the clinical and regulatory expertise of our three university founders, their Academic Health Science Centres (AHSCs) and National Institute for Health Research (NIHR) and Biomedical Research Centres (BRCs).
These close working relationships helps in the development of experimental medicine, a key element of translational research.